STIC Biotechnology Systems Branch

CRF Problem Report

The Biotechnology Systems Branch of the Scientific and Technical Information
Center (STIC) experienced a problem when processing the following computer
readable form (CRF):
Application Serial Number: 10/532,909 Filing Date: 10/13/2005 Date Processed by STIC: 08/22/2006
STIC Contact: Mark Spencer: Telephone: 571-272-2510; Fax: 571-273-0221
Nature of CRF Problem:
(circle one) Damaged or Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached) Empty file (filename present, but no bytes in file) (see attached) Wrong file saved to CRF (invention title, docket number, or applicant(s) do not match those in official application) (see attached) Not saved in ASCII text Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing. Did not contain a Sequence Listing. (see attached sample) Other: O
 EFS-Bio (<http: documents.htm="" downloads="" ebc="" efs="" www.uspto.gov="">, EFS Submission User Manual - ePAVE)</http:> U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Stree Alexandria, VA 22314
Revised 01/20/06

```
( Sample of Submittedfile)
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 9
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
                                           This is invalid
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: DNA
                                             Sequence Lishing
format. FYI: all
US applications which
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1
AACggatccaaaacgctgcctccgcga 27
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: DNA
                                               cannot claim a priol
(iv) ANTI-SENSE: YES
                                               application fled befole.

July 1st 1998 must be
en New Sequence Lules
format. This Sequence
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
TAGACGCTGCAGGAGGCGCCTGGCT 25
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 269 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3
See Sample
Sequence listing
attached for
valid format.
(A) LENGTH: 84 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULAR TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4
AGAAGACGAagctaagcagggtcgggcctggttagtacttggatgggagaccgcctggga 60
ataccgggtgctgtaggctttttg 84
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 88 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: DNA
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5
TCGACAAÄAAGCCTACAGCACCCGGTATTCCCAGGCGGTCTCCCATCCAAGTACTAACCA 60
GGCCCGACCCTGCTTAGCTTCGTCTTCT 88
```

- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 367 base pairs
- (B) TYPE: nucleic acid

Consult this

<110>	Smith, Jo	hn; Smithgen	e Inc.			
<120>	Example o	f a Sequence	Listing			
<130>	01-00001			÷	•	
<140> <141>	PCT/EP98/0 1998-12-31		:		•	. •
<150> <151>	US 08/999, 1997-10-15			•	٠	
<160>	.					
<170>	PatentIn v	ersion 2.0				. *
<210><211><212><213>	1 389 DNA Paramecium	sp.			*	
<220> <221> <222>	CDS (279)(3					
<300> <301> <302>	Doe, Richar Isolation	and Character	ization of a	Gene Encodia	ng a	
<303> <304> <305>	Journal of 1 4	rom Parameciu Genes	m sp.			
<306> <307> <308> <309>	1-7 1988-06-31 123456 1988-06-31	.•				
<400.> agctgtagtc	l attcctgtgt	cctcttctct.	ctgggcttct	caccctgcta	atcagatoto	60
agggagagtg	tcttgaccct	cctctgcctt	tgcagcttca	caggcaggca	ggcaggcagc	120
: tgatgtggca	attgctggca	gtgccacagg	cttttcagcc	aggettaggg	tgggttccgc	180
cgcggcgcgg	cggcccctct	cgcgctcctc	tcgcgcctct	ctctcgctct	cctctcgctc	240

```
cagttagc
                                                                       gtt
Val
 ggacctgatt aggtgagcag
                                                                 atg
                               gaggagggg
                                                                                    atg
                                                                                           ttc
                                                                                                 agc
Ser
                                                                              Ser
                                                                 Het
                                                                                    Met
                                                                                           Phe
                                                                       gtt
Val
       tct
                   Lys
10
                                                    Cys
15
       Ser
                                 Pro
                                       Ğİy
                                              Phe
                                                          Leu
                                                                 Phe
                                                                                    Leu
                  .gtc
Val
 tgt
                                 ccc
                                       tgt
                                              cac
                                                          tca
                                                                 ctg
                                                                       cag
                                                                             ccg
                                                                                                        389
                                                                                          Leu '
                          Leu
                                 Pro
                                       Cys
                                              His
                                                    Ser
                                                          Ser
                                                                 Leu
                                                                       Gln
                                                                             Pro
                                                                                    Asn
                                               30
                                                                               35
               2
37
 <210>
 <211>
 <212>
              · PRT
 <213>
               Paramecium sp.
<400>
                                                                           Gly
Met Val
                         Phe
                                Ser
                                      Leu
                                             Ser
                                                  Phe
                   Leu
                         Phe
                                Gln
                                             Pro
                                                                                   His
                                                                                                Ser
                                                                                    30
      Gln
             Pro
                   Asn
                         Leu
-<210>
<211>
<212>
               Artificial Sequence
<220>
               Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.
<400>
Met Val
            Asn Leu Glu
                               Pro Met
                                                         Glu
<210>
<400>
000
```

. .

•

....

tagentifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	м
` <120>	Title of Invention		м
<130>	File Reference	Personal'file reference	M when filed prior to assignment of appl. number
<140>	Current Applica- tion Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOS	M
<170>	Software	Name of software used to create the Sequence Listing	o .
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	м -
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	м .

			•
<212>	Туре	Whether presented sequence mole-cule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In ad-	M
⁻		dition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

	•	in feature ,	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is com-
With the second	\$ 40 mm		bined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	0
<301> ·	Authors	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials	o
<302>	Title		0 ;
<303>	Journal		o .
<304>	Volume		0
<305>	Issue		o
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm- dd, MMM-yyyy or Season-yyyy	о
<308>	Database Accession Number	Accession number assigned by data- base including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	o ·
<310>	Patent Document Number ,	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	a

<311>	Patent Filing Date	Document filing date, for patent- type citations only; specify as yyyy-mm-dd	0
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	0
<313>	Relevant Residueș	FROM (position) TO (position)	0
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line pre- ceding the actual sequence	М

5. Section 1.824 is revised to read as follows:

- 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.821(e) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:	
M BLACK BORDERS	
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES	
FADED TEXT OR DRAWING	
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING	
☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS	
GRAY SCALE DOCUMENTS	
LINES OR MARKS ON ORIGINAL DOCUMENT	
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY	

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.